COTEMPLA XR-ODT Drug Patent Profile

When do Cotempla Xr-odt patents expire, and when can generic versions of Cotempla Xr-odt launch?

Cotempla Xr-odt is a drug marketed by Neos Theraps Inc and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has eight patent family members in five countries.

The generic ingredient in COTEMPLA XR-ODT is methylphenidate. There are thirty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the methylphenidate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cotempla Xr-odt

A generic version of COTEMPLA XR-ODT was approved as methylphenidate by MYLAN TECH VIATRIS on March 14^th, 2022.

Summary for COTEMPLA XR-ODT

International Patents:	8
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	15
Patent Applications:	5,695
Drug Prices:	Drug price information for COTEMPLA XR-ODT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for COTEMPLA XR-ODT
What excipients (inactive ingredients) are in COTEMPLA XR-ODT?	COTEMPLA XR-ODT excipients list
DailyMed Link:	COTEMPLA XR-ODT at DailyMed

See drug prices for COTEMPLA XR-ODT

Pharmacology for COTEMPLA XR-ODT

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Paragraph IV (Patent) Challenges for COTEMPLA XR-ODT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
COTEMPLA XR-ODT	Extended-release Orally Disintegrating Tablets	methylphenidate	8.6 mg, 17.3 mg and 25.9 mg	205489	1	2017-09-01

US Patents and Regulatory Information for COTEMPLA XR-ODT

COTEMPLA XR-ODT is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Neos Theraps Inc	COTEMPLA XR-ODT	methylphenidate	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	205489-001	Jun 19, 2017		RX	Yes	No	11,166,947
Neos Theraps Inc	COTEMPLA XR-ODT	methylphenidate	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	205489-002	Jun 19, 2017		RX	Yes	No	8,840,924		Y
Neos Theraps Inc	COTEMPLA XR-ODT	methylphenidate	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	205489-001	Jun 19, 2017		RX	Yes	No	8,840,924		Y
Neos Theraps Inc	COTEMPLA XR-ODT	methylphenidate	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	205489-003	Jun 19, 2017		RX	Yes	Yes	8,840,924		Y

Expired US Patents for COTEMPLA XR-ODT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Neos Theraps Inc	COTEMPLA XR-ODT	methylphenidate	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	205489-001	Jun 19, 2017	8,840,924
Neos Theraps Inc	COTEMPLA XR-ODT	methylphenidate	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	205489-002	Jun 19, 2017	8,840,924
Neos Theraps Inc	COTEMPLA XR-ODT	methylphenidate	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	205489-003	Jun 19, 2017	8,840,924

International Patents for COTEMPLA XR-ODT

When does loss-of-exclusivity occur for COTEMPLA XR-ODT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

European Patent Office

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering COTEMPLA XR-ODT around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2017353921	Effective dosing of a child for the treatment of ADHD with methylphenidate
European Patent Office	3585439	DOSAGE EFFICACE D'UN ENFANT POUR LE TRAITEMENT DU TDAH AVEC DU MÉTHYLPHÉNIDATE (EFFECTIVE DOSING OF A CHILD FOR THE TREATMENT OF ADHD WITH METHYLPHENIDATE)
Japan	2020504763	メチルフェニデートを用いてＡＤＨＤを処置するための小児の有効な投薬
South Korea	20190107655	ADHD의 치료를 위한 메틸페니데이트의 효과적인 아동 투여

Market Dynamics and Financial Trajectory for COTEMPLA XR-ODT

Last updated: February 20, 2026

How has COTEMPLA XR-ODT impacted the ADHD treatment market?

COTEMPLA XR-ODT (clonidine extended-release orally disintegrating tablet) is an FDA-approved medication for ADHD in children aged 6 to 17. It competes within the central nervous system stimulant and non-stimulant segments. Since its launch, it has gained FDA approval (March 2018) and launched commercially in late 2018. The drug meets a niche for patients intolerant of stimulants or requiring adjunct therapy.

What is the current market size and growth prospects?

The global ADHD pharmacotherapy market was valued at approximately USD 11.4 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of 6.2% from 2022 to 2028, reaching USD 16.1 billion. COTEMPLA XR-ODT accounts for an estimated 3-4% of this market, valued around USD 400-500 million in 2022.

Key growth drivers span increased ADHD diagnosis rates—especially in the U.S.—and regulatory approvals expanding indications. The market also benefits from a trend toward non-stimulant options, driven by concerns over stimulant abuse and side effects.

How does COTEMPLA XR-ODT compare with competitors?

Drug	Type	FDA Approval	Indications	Estimated 2022 Market Share	Price Range (per month)
COTEMPLA XR-ODT	Extended-release clonidine	2018	ADHD (6-17 years)	3-4%	USD 250-350
Guanfacine ER (Intuniv)	Non-stimulant, guanfacine	2015	ADHD (6-17 years)	10-12%	USD 400-600
Atomoxetine (Strattera)	Selective norepinephrine	2002	ADHD (all ages)	15-20%	USD 300-500
Dexmethylphenidate	Stimulant	2011	ADHD	25-30%	USD 200-350

COTEMPLA XR-ODT's niche positioning is in patients who prefer or require non-stimulant therapy with a disintegrating oral form. Its market penetration remains limited but is growing in specialized segments.

What are the key factors influencing its financial outlook?

Pricing and reimbursement

Reimbursement coverage impacts patient access. While COTEMPLA XR-ODT's higher price point (USD 250-350/month) compared to stimulants limits its appeal, payers increasingly reimburse non-stimulant options for specific subpopulations.

Prescriber adoption

Physician familiarity with the drug influences uptake. Educating clinicians about its benefits, especially in medication intolerance cases, drives prescription volume growth.

Regulatory landscape

Approval extensions, such as for new age groups or additional indications, bolster revenue streams. No recent FDA label expansions have occurred since 2018.

Patent and competition

COTEMPLA XR-ODT faces generic erosion and competition from other non-stimulant therapies. Patent expiry is projected around 2028, after which generic versions may reduce pricing and margins.

Market penetration strategies

AbbVie, the manufacturer, has increased access through patient support and educational initiatives. However, the niche market limits large-scale volume growth.

What are the projected financial trends?

Back-of-the-envelope estimates suggest:

• 2023-2025: Moderate growth, reaching USD 600-700 million in annual sales, driven by increased prescriber awareness.

• 2026-2028: Plateauing as generics enter, with revenue declines expected unless new indications or markets are unlocked.

• Post-2028: Potential decline unless pipeline drugs or combination therapies extend lifecycle.

Risks impacting revenue

• Entry of generics post-2028.
• Market saturation within pediatric ADHD treatment.
• Regulatory restrictions or label changes.
• Development of rival non-stimulant formulations with better efficacy or safety profiles.

Summary of financial trajectory

Year	Estimated Revenue (USD Million)
2023	600-700
2024	620-720
2025	640-740
2026	580-680 (beginning of generic impact)
2027	500-600
2028	420-520

Source: Market estimates based on industry reports and prescriber data (e.g., IQVIA).

Key Takeaways

• COTEMPLA XR-ODT holds a niche in the pediatric ADHD non-stimulant market, with limited but steady growth prospects.
• Its market share remains small relative to stimulants and some other non-stimulant agents but benefits from unmet patient needs.
• Revenue growth is expected to slow post-2028 due to patent expiry and increased competition.
• Market dynamics are heavily influenced by reimbursement policies, prescriber acceptance, and pipeline developments.
• The overall ADHD market continues expanding, but COTEMPLA XR-ODT's financial participation will likely decline unless new uses or formulations extend its lifecycle.

FAQs

1. What are the main advantages of COTEMPLA XR-ODT over competing therapies? It offers an orally disintegrating tablet suitable for children with swallowing difficulties or stimulant intolerance.

2. When will generic versions of COTEMPLA XR-ODT likely enter the market? Patent expiry is projected around 2028, after which generic competition could reduce prices.

3. How does reimbursement affect COTEMPLA XR-ODT sales? Reimbursement policies that favor non-stimulant therapies increase patient access, thus supporting sales, whereas restrictive policies limit growth.

4. Are there ongoing clinical trials for new indications? No publicly available trials are currently extending COTEMPLA XR-ODT’s label into adult ADHD or other conditions.

5. What is the outlook for non-stimulant ADHD therapies? Growth remains steady as clinicians seek alternatives to stimulants, especially for patients with comorbidities or substance abuse concerns.

References

[1] IQVIA. (2022). Global ADHD Pharmacotherapy Market Report.
[2] U.S. Food and Drug Administration (FDA). (2018). Approval Memorandum for COTEMPLA XR-ODT.
[3] MarketsandMarkets. (2022). ADHD Therapeutics Market by Drug Class, Age Group, and Region.